IBBQ Fact Sheet: Invesco Nasdaq Biotechnology ETF
Share
$33.53
close, Nov 20, 2026
Over the year to Nov 18, 2026, IBBQ returned +24.7% in total and charged 0.19% a year.
- 1-year total return
- +23.6%
- to Nov 20, 2026
- Expense ratio
- 0.19%
- a year
- Net assets
- $124m
- on Nov 19, 2026
- Net flow, last 5 trading days
- +$3.2m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
IBBQ $12,474 +24.7% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month−4.9%
3 months−7.0%
Year to date+19.1%
1 year+23.6%
3 years+82.9%
5 years+45.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Gilead Sciences Inc9.41%
Amgen Inc8.44%
Vertex Pharmaceuticals Inc7.91%
Regeneron Pharmaceuticals Inc6.32%
Moderna Inc5.39%
Biogen Inc2.47%
Revolution Medicines Inc2.31%
Insmed Inc2.13%
Illumina Inc2.05%
Royalty Pharma PLC2.05%
IBBQ top ten by weight, 48.5% of the fund, of its 253 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 253 stocks in biotech, 43% of its weight in S&P 500 companies · First traded Jun 11, 2021 · Benchmark Its own holdings, as of Nov 19, 2026